DD Support Board and Research Team

[stockmasterflash]

MMRF

(operation Mole guy) never lets a good tragedy go to waste. Apparently Ebola researchers only need an IP license to find a cure for Ebola. ROTFL

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104962803

gopack Member Level Monday, 08/04/14 02:57:05 PM
Re: None
Post # of 72872
WOW just posted on the MMRGlobal Facebook Page! -

MMRGlobal Plans on Granting Royalty free licenses to Universities interested in Research using the Company’s “Antibodies and Methods for Making and Using Them” in Ebola Fight.

STORY FROM CNN Regarding Monoclonal Antibodies used in fight to save Ebola workers.

Three top secret, experimental vials stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment. According to CNN four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four additional monkeys that started therapy within 48 hours after infection also survived. One monkey that was not treated died within five days of exposure to the virus. The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.

MMRGlobal’s biotech intellectual property portfolio also includes patents and other pending applications directed to "Antibodies and Methods for Making and Using Them." The first U.S. patent protecting anti-CD20 monoclonal antibodies was issued in mid-2013 (Patent No. 8,465,741), followed by the first Australian patent (2007338607) and thereafter South Korean patent (10-2009-7015196) providing market protection of our specific antibodies that have particular utility infighting cancers. These newly issued patents are in addition to the Mexican patent granted in 2012 for the antibody assets. Patents for our antibodies are also pending in a number of additional countries including the United States, Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea. In light of the humanitarian crisis from Ebola and other diseases MMR plans on granting royalty free licenses to universities for research into the development of these and other biotech assets to create treatments for Ebola and other diseases. http://www.cnn.com/2014/08/04/health/experimental-ebola-serum/index.html?hpt=hp_t1

For additional information contact investor relations at www.mmrglobal.com